Skip to main content

restor3d

HardwareDurham, North Carolina, USAFounded 2017· One of 1636 Hardware companies tracked by AMPulse

3D printed, personalized orthopedic implants designed to improve surgical outcomes using advanced 3D printing, AI-driven design, and osseointegrative materials.

CEO / Founder
Kurt Jacobus
Team Size
51-200
Stage
Active
Total Funding
$212M
Latest Round
Strategic Investment
Key Investors
Partners Group, Summers Value Partners, Trinity Capital

Technology & Products

Key Products

restor3d specializes in personalized, 3D-printed orthopedic implants for shoulder, ankle, knee, and hip replacements. Key products include the Aeros Modular Stem System for total ankle replacement and the Ossera AFX Ankle Fusion Cage System.

Technical position · AMPulse analysis

Holds proprietary expertise and intellectual property in 3D printing and implant design, enabling highly customized implant solutions.

Patent position

restor3d filed 5 patent families in 2022-2024, flat against 5 in 2019-2021 (0%), while tracked AM filings in the same patent offices fell 36%. It has 10 families across all years, against 124 for Carbon and 114 for Formlabs. AMPulse analysis

Filing momentum
5 families filed 2022–2024, 5 in 2019–2021 (0%); all tracked AM filings in the same offices -36%
Focus, 2019–2021 → 2022–2024
Applications 100% → 100%
Filed in
US 100%
Named competitors, AM patent families
Carbon 124Formlabs 114

10 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Offers patient-specific implants with optimal anatomical fit using advanced 3D printing, AI-driven design automation, and osseointegrative materials to enhance surgical precision and patient recovery.

How They Differentiate

Focus on patient-specific, 3D printed implants using AI-driven design for superior anatomical fit and enhanced osseointegration compared to traditional implant solutions.

Market & Competition

Target Customers

Orthopedic surgeons, hospitals, and medical centers.

Industry Verticals

Orthopedic Surgery, Medical Devices, 3D Printing/Additive Manufacturing

Competitors

Carbon; Formlabs; Stryker

Growth & Milestones

Growth Metrics

Rapid expansion with new product launches planned in 2025-2026; approaching positive operating cash flow.

Major Milestones

FDA 510(k) clearance for the iTotal Identity Total Knee Replacement System, Merger with Kinos Medical to accelerate expansion into extremity arthroplasty markets, Move into a new facility in Research Triangle Park to boost digital design and in-house manufacturing capabilities, Multiple successful funding rounds including a $70M Series A and a recent $38M growth round

https://www.restor3d.com

Recent coverage of restor3d

AM patents

AM-relevant patents linked to this company.

Patents
11
Granted
11
Families
10

Leading domains: application (11), process (6), software (2)

Filings by year: 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1

  1. Sheet based triply periodic minimal surface implants for promoting osseointegration and methods for producing same11484413 · US
  2. Custom surgical devices and method for manufacturing the same10889053 · US
  3. Surgical guides and processes for producing and using the same12042159 · US
  4. Sheet based triply periodic minimal surface implants for promoting osseointegration and methods for producing same12653680 · US
  5. Patient-specific medical devices and additive manufacturing processes for producing the same12265373 · US

Funding rounds

  • Strategic Investment$104.0M2025-08-22Lead: Partners Group
  • Growth Round$38.0M2025-04-04Lead: Summers Value Partners
  • Series A$70.0M2024-06-05Lead: Summers Value Partners

Why this company matters

AMPulse analysis, not a company disclosure

Restor3d occupies a distinct position in the orthopedic implant market by combining patient-specific design with metal powder bed fusion (PBF-LB) and proprietary osseointegrative materials. Unlike traditional off-the-shelf implants, the company's approach aims to improve anatomical fit and surgical precision through AI-driven design automation.

The company's core technology centers on metal PBF-LB 3D printing, which enables the fabrication of complex porous structures intended to promote bone ingrowth. Key products include the Aeros Modular Stem System for total ankle replacement and the Ossera AFX Ankle Fusion Cage System. Restor3d also holds FDA 510(k) clearance for the iTotal Identity Total Knee Replacement System.

Target customers are orthopedic surgeons, hospitals, and medical centers. The company has partnered with Duke University and merged with Kinos Medical to expand into extremity arthroplasty. With $212 million in total funding from investors including Partners Group, Summers Value Partners, and Trinity Capital, restor3d is approaching positive operating cash flow and plans new product launches in 2025-2026.

The primary competitive risk comes from large orthopedic players like Stryker and from additive manufacturing platforms such as Carbon and Formlabs that also target medical implants. Restor3d's moat rests on its combination of AI design automation, proprietary implant IP, and regulatory clearances, but the company must continue to demonstrate clinical outcomes that justify the premium for personalized implants over standard alternatives.